- Home
- PPBI vs RDY Comparison
PPBI vs RDY Comparison
Compare PPBI & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBI
- RDY
- Stock Information
- Founded
- PPBI 1983
- RDY 1984
- Country
- PPBI United States
- RDY India
- Employees
- PPBI N/A
- RDY N/A
- Industry
- PPBI Major Banks
- RDY Biotechnology: Pharmaceutical Preparations
- Sector
- PPBI Finance
- RDY Health Care
- Exchange
- PPBI Nasdaq
- RDY Nasdaq
- Market Cap
- PPBI 2.5B
- RDY 2.5B
- IPO Year
- PPBI 1997
- RDY N/A
- Fundamental
- Price
- PPBI $24.12
- RDY $13.35
- Analyst Decision
- PPBI Buy
- RDY Buy
- Analyst Count
- PPBI 6
- RDY 1
- Target Price
- PPBI $27.00
- RDY $17.00
- AVG Volume (30 Days)
- PPBI 549.7K
- RDY 1.8M
- Earning Date
- PPBI 01-23-2025
- RDY 01-23-2025
- Dividend Yield
- PPBI 5.33%
- RDY 3.60%
- EPS Growth
- PPBI 438.96
- RDY 2.68
- EPS
- PPBI 1.65
- RDY 0.75
- Revenue
- PPBI $615,000,000.00
- RDY $3,637,607,642.00
- Revenue This Year
- PPBI N/A
- RDY $17.23
- Revenue Next Year
- PPBI $3.81
- RDY $9.20
- P/E Ratio
- PPBI $15.04
- RDY $17.68
- Revenue Growth
- PPBI 39.71
- RDY 14.74
- 52 Week Low
- PPBI $20.52
- RDY $13.16
- 52 Week High
- PPBI $30.28
- RDY $16.89
- Technical
- Relative Strength Index (RSI)
- PPBI 37.56
- RDY 33.41
- Support Level
- PPBI $24.92
- RDY $13.16
- Resistance Level
- PPBI $25.75
- RDY $13.46
- Average True Range (ATR)
- PPBI 0.68
- RDY 0.15
- MACD
- PPBI -0.15
- RDY -0.01
- Stochastic Oscillator
- PPBI 5.56
- RDY 21.02
About PPBI Pacific Premier Bancorp Inc
Pacific Premier Bancorp Inc through its subsidiaries, provides banking products and services. It offers cash management, electronic banking services, credit facilities, and retirement accounts, among others.
About RDY Dr. Reddy's Laboratories Ltd
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.